- Home
- VGI vs ACRV Comparison
VGI vs ACRV Comparison
Compare VGI & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VGI | ACRV |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.7M | 74.0M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | VGI | ACRV |
|---|---|---|
| Price | $6.72 | $2.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 42.6K | ★ 291.5K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 12.66% | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.66 | $1.27 |
| 52 Week High | $8.04 | $3.56 |
Technical Indicators
Market Signals| Indicator | VGI | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 25.87 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $7.99 | N/A |
| Average True Range (ATR) | 0.12 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 16.36 | 0.00 |
Price Performance
Historical ComparisonAbout VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.